SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Massimo Breccia, Matteo Molica, Giuliana Alimena, Updated review of nilotinib as frontline treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia, Clinical Investigation, 2015, 5, 3, 257

    CrossRef

  2. 2
    Peter B. Kooten Niekerk, Charlotte C. Petersen, Charlotte G. Nyvold, Hans B. Ommen, Anne S. Roug, Line Nederby, Peter Hokland, Eigil Kjeldsen, Cell sorting enables interphase fluorescence in situ hybridization detection of low BCR-ABL1 producing stem cells in chronic myeloid leukaemia patients beyond deep molecular remission, British Journal of Haematology, 2014, 164, 1
  3. 3
    Massimo Breccia, Giuliana Alimena, Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: Treatment-free remission as a new goal in chronic myeloid leukemia, Cancer Letters, 2014, 347, 1, 22

    CrossRef

  4. 4
    S Mustjoki, J Richter, G Barbany, H Ehrencrona, T Fioretos, T Gedde-Dahl, B T Gjertsen, R Hovland, S Hernesniemi, D Josefsen, P Koskenvesa, I Dybedal, B Markevärn, T Olofsson, U Olsson-Strömberg, K Rapakko, S Thunberg, L Stenke, B Simonsson, K Porkka, H Hjorth-Hansen, Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients, Leukemia, 2013, 27, 7, 1520

    CrossRef

  5. 5
    Pratap Neelakantan, Jane F Apperley, Nilotinib for treatment of chronic myeloid leukemia in light of the current evidence and guidelines, Clinical Practice, 2013, 10, 3, 283

    CrossRef

  6. 6
    Andreas Hochhaus, Hagop Kantarjian, The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients, Journal of Cancer Research and Clinical Oncology, 2013, 139, 12, 1971

    CrossRef